UGT1A1*6 ALLELE FREQUENCY IN VIETNAMESE KINH ETHNIC GROUP

Nguyễn Đăng Tôn; Nguyễn Thị Thanh Hoa; Nguyễn Hoài Nam; Vũ Phương Nhung; Hoàng Thị Thu Yến; Nguyễn Hải Hà

UGT1A1*6 ALLELE FREQUENCY IN VIETNAMESE KINH ETHNIC GROUP

About this article

Received: 08/01/21 Revised: 08/04/21 Published: 12/04/21

Authors

1. Nguyen Dang Ton, Institute of genome research - VAST Graduate University of Science and - VAST
2. Nguyen Thi Thanh Hoa, Institute of genome research - VAST
3. Nguyen Hoai Nam, Institute of genome research - VAST
4. Vu Phuong Nhung, Institute of genome research - VAST
5. Hoang Thi Thu Yen , TNU - University of Sciences
6. Nguyen Hai Ha, Institute of genome research - VAST Graduate University of Science and - VAST

Abstract

UGT1A1 is believed to have been associated with neutropenia and diarrhea side effects when using irinotecan in the treatment of cancer patients. Some variants of UGT1A1 cause sufficiently serious side effects leading to the need to reduce the dose or stop cancer treatment with irinotecan. The UGT1A1*6 variant is believed to increase the risk of neutropenia and is closely related to the risk of severe diarrhea in Asian cancer patients. In this study, we used the direct sequencing method exon 1 fragment of UGT1A1 gene to determine the genotype and allele frequency of UGT1A1*6 in 96 individuals of healthy Kinh ethnic group. The results showed that UGT1A1*6 variant is present in homozygous and heterozygous genotypes with frequencies of 21.875% (n=21) and 3.125% (n=3), respectively. The allele frequency of the UGT1A1*26 variant was 14.063% which was small compared with the wild type allele *1 (85.937%). The data obtained from the study contribute to an effective cancer treatment solution using the drug irinotecan.

Keywords

Irinotecan; UDP-glycosyltransferase; UDP Glucuronosyltransferase Family 1 Member A1 (UGT1A1); UGT1A gene; UGT1A1*6

Full Text:

PDF (Tiếng Việt)

References

[1] C.N. Sanchez-Dominguez, H.L. Gallardo-Blanco, M.A. Salinas-Santander, and R. Ortiz-Lopez, "Uridine 5'-diphospho-glucronosyltrasferase: Its role in pharmacogenomics and human disease,"Exp. Ther. Med., vol. 16, no. 1, pp. 3-11, 2018.

[2] G. Steventon, "Uridine diphosphate glucuronosyltransferase 1A1,"Xenobiotica, vol. 50, no. 1, pp. 64-76, 2020.

[3] K. Osawa, "Gene Polymorphisms and Chemotherapy in Non-small Cell Lung Cancer,"Chinese Journal of lung cancer, vol. 12, no. 8, pp. 837-840, 2009.

[4] R. Meech, D.G. Hu, R.A. Mckinnon, S.N. Mubarokah, A.Z. Haines, P.C. Nair, A. Rowland, and P.I. Mackenzie, "The UDP-Glycosyltransferase (UGT) Superfamily: New Members, New Functions, and Novel Paradigms,"Physiol Rev, vol. 99, no. 2, pp. 1153-1222, 2019.

[5] H.J. Edenberg, and J.N. Mcclintick, "Alcohol Dehydrogenases, Aldehyde Dehydrogenases, and Alcohol Use Disorders: A Critical Review,"Alcohol Clin Exp Res, vol. 42, no. 12, pp. 2281-2297, 2018.

[6] H. Jinno, T. Tanaka-Kagawa, N. Hanioka, M. Saeki, S. Ishida, T. Nishimura, M. Ando, Y. Saito, S. Ozawa, and J. Sawada, "Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D,"Drug Metab Dispos, vol. 31, no. 1, pp. 108-113, 2003.

[7] K. Sai, and Y. Saito, "Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs,"Expert Opin Drug Metab Toxicol, vol. 7, no. 8, pp. 967-988, 2011.

[8] L. Dean, "Irinotecan Therapy and UGT1A1 Genotype,"in Medical Genetics Summaries Bethesda (MD), USA: National Center for Biotechnology Information, 2015, pp. 235-246.

[9] S.C. Marques, and O.N. Ikediobi, "The clinical application of UGT1A1 pharmacogenetic testing: gene-environment interactions,"Hum Genomics, vol. 4, no. 4, pp. 238-249, 2010.

[10] UGT1A and UGT2B haplotypes and SNPs tables. [Online]. Available:https://www.pharmacogenomics.pha.ulaval.ca/ugt-alleles-nomenclature. [Accessed Jan. 09, 2020].

[11] T.T. Nguyen, W. Zhao, X. Yang, and D.N. Zhong, "The relationship between hyperbilirubinemia and the promoter region and first exon of UGT1A1 gene polymorphisms in Vietnamese newborns,"Pediatr Res, vol. 88, no. 6, pp. 940-944, 2020.

[12] R. Shakibi, B. Kamalidehghan, F. Ahmadipour, G.Y. Meng, and M. Houshmand, "Prevalence of the UGT1A1*6 (c.211G>A) Polymorphism and Prediction of Irinotecan Toxicity in Iranian Populations of Different Ethnicities,"Chemotherapy, vol. 60, no. 5-6, pp. 279-287, 2014.

[13] A. Zhang, Q. Xing, S. Qin, J. Du, L. Wang, L. Yu, X. Li, L. Xu, M. Xu, G. Feng, and L. He, "Intra-ethnic differences in genetic variants of the UGT-glucuronosyltransferase 1A1 gene in Chinese populations,"Pharmacogenomics J., vol. 7, no. 5, pp. 333-338, 2007.

[14] S. Chen, L. Hua, C. Feng, Q. Mo, M. Wei, Y. Shen, Z. Lin, G. Li, J. Xu, C. Guo, and H. Huang, "Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang,"BMC Gastroenterol, vol. 20, no. 1, p. 96, 2020.

[15] X. Zhang, X. Meng, Y. Wang, W. Yan, and J. Yang, "Comprehensive analysis of UGT1A1 genetic polymorphisms in Chinese Tibetan and Han populations,"Biochem Genet, vol. 50, no. 11-12, pp. 967-977, 2012.

[16] M. Kobayashi, S. Hazama, K. Takahashi, K. Oba, N. Okayama, M. Nishioka, Y. Hinoda, M. Oka, K. Okamoto, H. Maeda, D. Nakamura, J. Sakamoto, and H. Mishima, "Is there diversity among UGT1A1 polymorphism in Japan?"World J Gastrointest Oncol, vol. 4, no. 7, pp. 170-175, 2012.

[17] S.R. Jada, R. Lim, C.I. Wong, X. Shu, S.C. Lee, Q. Zhou, B.C. Goh, and B. Chowbay, "Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients,"Cancer Sci, vol. 98, no. 9, pp. 1461-1467, 2007.

[18] L.K. Teh, H. Hashim, Z.A. Zakaria, and M.Z. Salleh, "Polymorphisms of UGT1A1*6, UGT1A1*27 & UGT1A1*28 in three major ethnic groups from Malaysia,"Indian J Med Res, vol. 136, no. 2, pp. 249-259, 2012.

[19]. N. Kaniwa, K. Kurose, H. Jinno, T. Tanaka-Kagawa, Y. Saito, M. Saeki, J. Sawada, M. Tohkin, and R. Hasegawa, "Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C> T (P229L) found in an African-American,"Drug Metab Dispos, vol. 33, no. 3, pp. 458-465, 2005.

[20] C.S. Huang, G.A. Luo, M.L. Huang, S.C. Yu, and S.S. Yang, "Variations of the bilirubin uridine-diphosphoglucuronosyl transferase 1A1 gene in healthy Taiwanese,"Pharmacogenetics, vol. 10, no. 6, pp. 539-544, 2000.

[21] R. Amandito, R. Rohsiswatmo, E. Carolina, R. Maulida, W. Kresnawati, and A. Malik, "Profiling of UGT1A1(*)6, UGT1A1(*)60, UGT1A1(*)93, and UGT1A1(*)28 Polymorphisms in Indonesian Neonates With Hyperbilirubinemia Using Multiplex PCR Sequencing,"Front Pediatr, vol. 7, no. 328 pp. 1-9, 2019.

[22] H. Maeda, S. Hazama, A. Shavkat, K. Okamoto, K. Oba, J. Sakamoto, K. Takahashi, M. Oka, D. Nakamura, R. Tsunedomi, N. Okayama, H. Mishima, and M. Kobayashi, "Differences in UGT1A1, UGT1A7, and UGT1A9 polymorphisms between Uzbek and Japanese populations,"Mol Diagn Ther, vol. 18, no. 3, pp. 333-342, 2014.

[23] X. Zhang, J.F. Yin, J. Zhang, S.J. Kong, H.Y. Zhang, and X.M. Chen, "UGT1A1*6 polymorphisms are correlated with irinotecan-induced neutropenia: a systematic review and meta-analysis,"Cancer Chemother Pharmacol, vol. 80, no. 1, pp. 135-149, 2017.

[24] L. Cheng, M. Li, J. Hu, W. Ren, L. Xie, Z.P. Sun, B.R. Liu, G.X. Xu, X.L. Dong, and X.P. Qian, "UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians,"Cancer Chemother Pharmacol, vol. 73, no. 3, pp. 551-560, 2014.

[25] C. Atasilp, P. Chansriwong, E. Sirachainan, T. Reungwetwattana, M. Chamnanphon, A. Puangpetch, S. Wongwaisayawan, and C. Sukasem, "Correlation of UGT1A1(*)28 and (*)6 polymorphisms with irinotecan-induced neutropenia in Thai colorectal cancer patients,"Drug Metab Pharmacokinet, vol. 31, no. 1, pp. 90-94, 2015.

[26] J. Gao, J. Zhou, Y. Li, M. Lu, R. Jia, and L. Shen, "UGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients,"Med Oncol, vol. 30, no. 3, pp. 604, 2013.

[27] X. Zhu, R. Ma, X. Ma, and G. Yang, "Association of UGT1A1*6 polymorphism with irinotecan-based chemotherapy reaction in colorectal cancer patients: a systematic review and a meta-analysis,"Biosci Rep, vol. 40, no. 10, pp. 1-17, 2020.

[28] H. Fujii, Y. Yamada, D. Watanabe, N. Matsuhashi, T. Takahashi, K. Yoshida, and A. Suzuki, "Dose adjustment of irinotecan based on UGT1A1 polymorphisms in patients with colorectal cancer,"Cancer Chemother Pharmacol, vol. 83, no. 1, pp. 123-129, 2019.

[29] K. Fujita, Y. Kubota, H. Ishida, and Y. Sasaki, "Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer,"World J Gastroenterol, vol. 21, no. 43, pp. 12234-12248, 2015.

Refbacks

There are currently no refbacks.



Remember me